Juveena Hydrogel System
Rejoni, Inc. · Decision date Oct 28, 2026
What did the FDA decide?
The FDA database records a 30-Day Notice for the Juveena Hydrogel System, submitted by Rejoni, Inc. The stated purpose is a change to remove visible particulates prior to final packaging. The supplement type is a Process Change involving the Manufacturer/Sterilizer/Packager/Supplier, and the decision is recorded as OK30.
This notice is not a new approval of the whole system and does not establish safety or clinical effectiveness. The device is classified as a barrier, absorbable, adhesion product under product code MCN in Obstetrics/Gynecology. The source statement does not specify the particulate removal method, the manufacturing stage affected, or any resulting performance data.
FDA approval order statement
a change to remove visible particulates prior to final packaging
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250051/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Rejoni, Inc.
- Product code
- MCN
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Barrier, absorbable, adhesion.
- Applicant
- Rejoni, Inc.
- Product code
- MCN
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250051. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250051 · Original PMA
Juveena Hydrogel System
P250051/S001 received
Application receipt date recorded by FDA.
P250051/S001 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250051. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250051
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juveena Hydrogel SystemP250051 | Rejoni, Inc. | PMA approval | Sep 28, 2026 | FDA |
Explore the linked device profile
Other records with product code MCN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GYNECARE INTERCEED Absorbable Adhesion BarrierP880047/S072 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Womed LeafP240015/S003 | Womed Sas | PMA supplement | Oct 25, 2026 | FDA |
| Womed Sas | PMA approval | Sep 9, 2025 | FDA | |
| ETHICON, Inc. | PMA approval | Sep 15, 1989 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Rejoni, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Second Floor, Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250051/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


